News
Public · Published
Key facts: Outlook Up; Norovirus Miss; mFLUSIVA Approved, Melanoma Data Positive
Moderna reported third-quarter revenue of $1.313 billion, up 29%, and net income of $162 million, compared with a loss a year earlier. It raised its 2026 revenue growth outlook to 15%–25%; its norovirus trial missed interim early-success criteria, while mFLUSIVA was approved and melanoma results were positive.
Published:
Updated:
What happened
Moderna reported third-quarter revenue of $1.313 billion, up 29%, and net income of $162 million, compared with a loss a year earlier. It raised its 2026 revenue growth outlook to 15%–25%; its norovirus trial missed interim early-success criteria, while mFLUSIVA was approved and melanoma results were positive.
Confirmed
Global impact / market context
Higher growth guidance and a return to quarterly net income point to improving near-term sales and earnings. The norovirus setback may delay that vaccine’s development, while mFLUSIVA approval and positive melanoma results could support future revenue, but the article gives no sales forecasts or launch details.
Analyst inference
The update combines stronger reported financial results with mixed pipeline news: one vaccine trial missed its early-success criteria, while another vaccine was approved and melanoma data were positive. Investors may weigh current performance more heavily until the article provides evidence of commercial uptake or further trial progress.
Analyst inference
What to watch
- Watch whether Moderna’s next financial updates show revenue growth within its 15%–25% outlook and continued net income; the article provides no quarterly breakdown or earnings forecast. Analyst inference
- Moderna said it will consult health officials about next steps after the norovirus trial miss; any resulting change to development plans could affect timing and spending. Confirmed
- Track whether mFLUSIVA approval is followed by information on availability and sales, since approval alone does not establish how much revenue the vaccine will generate. Analyst inference
Evidence
- Original source link unavailable